NeuBase Therapeutics Inc
(NAS:NBSE)
$
0.378
-0.012499 (-3.2%)
Market Cap: 1.42 Mil
Enterprise Value: -5.82 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 20/100 
NeuBase Therapeutics Inc at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript
May 19, 2021 / 03:30PM GMT
Release Date Price:
$100.2
(-3.84%)
Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst
Hi. Welcome back, everyone. I'm Brian Abrahams, senior biotech analyst here at RBC Capital Markets. We're really glad to have our next presenting company, NeuBase Therapeutics, represented by their CEO, Dietrich Stephan. Dietrich, thanks so much for joining us.
Dietrich A. Stephan
NeuBase Therapeutics, Inc. - Founder, President, CEO & Chairman
Hi, Brian, thanks for having us.
Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst
Our pleasure.
Questions & Answers
Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst
So maybe just to kick things off for those who are newer to the NeuBase story. Can you walk us through the main advantages of the PNA technology approach that you guys -- that forms the foundation of the company when it comes to drug development. And maybe also touch upon why PNAs
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers